Fujifilm Owns Japanese Drug Company Offering Influenza Drug As Potential Ebola Treatment

The New Yorker: How Fujifilm Came to the Ebola Fight
“…Japan said that Fujifilm was offering up the drug, Favipiravir, [which is made by Toyama Chemical, a company Fujifilm acquired five years ago,] as a potential stopgap in the fight against an outbreak of Ebola that has, according to the World Health Organization, killed nineteen hundred people in West Africa, and that Médecins Sans Frontières just called for a global military and civilian response to stop…” (Hunt, 9/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.